Partial budget of the discounted annual benefit of mastitis control strategies

The Economic Evaluation of Mastitis Control Strategies in Holstein-Friesian Dairy Herds

The economic evaluation of mastitis control is challenging. The objective of this study was to perform the economic evaluation of mastitis control, under different intervention scenarios, quantifying the total cost of mastitis caused by S. aureus in Holstein cows in Argentina. A model was set for a dairy herd of Holstein cows endemically infected with S. aureus. A basic mastitis control plan including proper milking procedures, milking machine test, dry cow therapy, and treatment for clinical mastitis, was compared against other more complex and costly interventions, such as segregation and culling of chronically infected cows. Sensitivity analysis was performed by modifying the intramammary infection transition probabilities, economic parameters, and efficacy of treatment strategies. The basic mastitis control plan showed a median total cost of USD88.6/cow per year, which was close to the infected cows culling scenarios outputs. However, the segregation scenario was the most efficient, in which the total cost was reduced by about 50%. Such cost was more sensitive to probabilities and efficacy than the economic parameters. The model is flexible and can be customized by producers and veterinarians according to different control and herd settings.

Stochastic partial budget analysis of strategies to reduce the prevalence of lung lesions in finishing pigs at slaughter

Ante- and post-mortem inspections of food-producing animals at slaughter are mandatory activities carried out in many countries to ensure public health, animal health, and meat quality. In finishing pigs, lung lesions are the most frequent defects found in meat inspections. It is possible to implement managerial strategies on-farm to reduce the occurrence and spread of respiratory diseases, but such strategies come with additional costs that could impede implementation. This study assessed the economic impact of two strategies aimed at reducing the prevalence of lung lesions in finishing pigs at slaughter by improving the health conditions of the animals during the production cycle. First, a farrow-to-finish pig farm with 355 sows was modeled based on the current standard practice for finishing pig production in Sweden, using economic data, meat inspection data and biological variables from the literature and expert opinions. A partial budget analysis was then performed in which the baseline farm was compared with two hypothetical strategies aimed at reducing the occurrence and spread of respiratory diseases during pig production: (S1) avoiding mixing of litters after weaning and (S2) keeping purchased pregnant gilts separated from sows during gestation, farrowing and lactation. Both these strategies intended to reduce the occurrence of respiratory disease in finishing pigs at slaughter gave an average gain in annual net income (33,805 SEK in S1 and 173,160 SEK in S2, equal to 3,146€ and 16,113€, respectively, at the time of analysis), indicating that both were economically sustainable under the assumed conditions. The impact analysis of the two strategies revealed that the reduced prevalence of lung lesions when adopting one of the strategies was the most influential factor in net benefit change on the farm. Overall, the results suggest that with the increasing prevalence of lung lesions in Swedish pig production (as also observed worldwide in recent years), adopting an effective strategy to decrease respiratory infections will become more relevant and economically beneficial.

Invited review: Incidence, risk factors, and effects of clinical mastitis recurrence in dairy cows

Clinical mastitis (CM) is one of the most frequent and costly diseases in dairy cows. A frustrating aspect of CM is its recurrent nature. This review was conducted to synthesize knowledge on risk of repeated cases of CM, effects of recurrent CM cases, and risk factors for CM recurrence. A systematic review methodology was used to identify articles for this narrative review. Searches were performed to identify relevant scientific literature published after 1989 in English or French from 2 databases (PubMed and CAB Abstracts) and 1 search platform (Web of Science). Fifty-seven manuscripts were selected for qualitative synthesis according to the inclusion criteria. Among the 57 manuscripts selected in this review, a description of CM recurrence, its risk factors, and effects were investigated and reported in 33, 37, and 19 selected manuscripts, respectively. Meta-analysis and meta-regression analyses were used to compute risk ratio comparing risk of CM in cows that already had 1 CM event in the current lactation with risk of CM in healthy cows. For these analyses, 9 manuscripts that reported the total number of lactations followed and the number of lactations with ≤1 and ≤2 CM cases were used. When summarizing results from studies requiring ≥5 d between CM events to consider a CM event as a new case, we observed no significant change in CM susceptibility following a first CM case (risk ratio: 0.99; 95% confidence interval: 0.86-1.14). However, for studies using a more liberal CM recurrence definition (i.e., only 24 h between CM events to consider new CM cases), we observed a 1.54 times greater CM risk (95% confidence interval: 1.20-1.97) for cows that already had 1 CM event in the current lactation compared with healthy cows. The most important risk factors for CM recurrence were parity (i.e., higher risk in older cows), a higher milk production, pathogen species involved in the preceding case, and whether a bacteriological cure was observed following the preceding case. The most important effects of recurrent CM were the milk yield reduction following a recurrent CM case, which was reported to be similar to that of the first CM case, and the increased risk of culling and mortality, which were reported to surpass those of first CM cases.

Optimally achieving milk bulk tank somatic cell count thresholds

High somatic cell count in milk leads to reduced shelf life in fluid milk and lower processed yields in manufactured dairy products. As a result, farmers are often penalized for high bulk tank somatic cell count or paid a premium for low bulk tank somatic cell count. Many countries also require all milk from a farm to be lower than a specified regulated somatic cell count. Thus, farms often cull cows that have high somatic cell count to meet somatic cell count thresholds. Rather than naïvely cull the highest somatic cell count cows, a mathematical programming model was developed that determines the cows to be culled from the herd by maximizing the net present value of the herd, subject to meeting any specified bulk tank somatic cell count level. The model was applied to test-day cows on 2 New York State dairy farms. Results showed that the net present value of the herd was increased by using the model to meet the somatic cell count restriction compared with naïvely culling the highest somatic cell count cows. Implementation of the model would be straightforward in dairy management decision software.

Deterministic model to evaluate the impact of lactational treatment of subclinical mastitis due to coagulase-negative staphylococci

Coagulase-negative staphylococci (CNS) are the most frequently isolated bacteria from milk samples in several studies worldwide. Despite their relative frequency, specific measures aiming at their control are not well established. One possible measure to include in a control programme is lactational antimicrobial treatment. The decision to perform such treatment, as well as other actions on farm, should be based on the likelihood of financial return. A deterministic model was used to evaluate whether performing an antimicrobial treatment during the lactation for quarters infected with CNS was financially justifiable. Input variables for the impact of CNS on udder health were based on a previous study by the same authors and on available literature on the subject. Prices included in the model were based on 2009/2010 conditions in Portugal. The average result per antimicrobial treated quarter was a net loss of €38·74. Performing a sensitivity analysis to evaluate how systematic variation of the input variables of the model would lead to outcome changes showed that variation in input variables nearly always led to a negative outcome, with the greatest variation in losses observed for variation in the length of treatment and milk withdrawal period (-€46·26 to -€28·49). The situations in which a net benefit was to be expected included the bulk tank somatic cell count decreasing to a level corresponding to a premium payment or to penalties being avoided, and the prevention of transmission of CNS in the milking parlour when the possibility of transmission was at its highest level. For most situations, lactational treatment of CNS subclinical mastitis was not financially justifiable.

Economic aspects of mastitis: new developments

Good udder health is not only important for the dairy farmer but, because of increasing interest of consumers in the way dairy products are produced, also for the dairy production chain as a whole. An important role of veterinarians is in advising on production diseases such as mastitis. A large part of this advice is given around the planning of management to maintain or improve the udder health status of a farm. Mastitis is a costly disease, due to losses (a reduction of output due to mastitis) and expenditure (additional inputs to reduce the level of mastitis). Worldwide, published estimates of the economic losses of clinical mastitis range from €61 to €97 per cow on a farm, with large differences between farms, e.g. in The Netherlands, losses due to clinical and subclinical mastitis varied between €17 and €198 per cow per year. Moreover, farmers tended to underestimate these costs. This indicates that for a large proportion of farms there are many avoidable losses. In order to provide good support to farmers' decision-making, it is important to describe the mastitis setting not only in terms of disease, e.g. incidence of clinical mastitis, but also in monetary terms; and to make good decisions, it is necessary to provide the dairy farmer with information on the additional expenditure and reduced losses associated with alternative decisions. Six out of 18 preventive measures were shown to have a positive nett benefit, viz blanket use of dry-cow therapy, keeping cows standing after milking, back-flushing of the milk cluster after milking a cow with clinical mastitis, application of a treatment protocol, washing dirty udders, and the use of milkers' gloves. For those measures that included a large amount of routine labour or investment, the reduced losses did not outweigh the additional expenditure. The advisor cannot expect that measures that are cost-effective are always implemented. Reasons for this are the objectives of the dairy farmer can be other than maximisation of profit, resources to improve the mastitis situation compete with other fields of management, risk involved with the decision, economic behaviour of the dairy farmer, and valuation of the cost factors by the dairy farmer. For all decision-makers this means that, although financial incentives do have an effect on the management of mastitis, it is not always sufficient to show the economic benefits of improved management to induce an improvement of management of mastitis.

Pharmacokinetics and efficacy of teicoplanin against intramammary infections in sheep

The pharmacokinetics of teicoplanin were evaluated in 10 healthy sheep. After intravenous injection it showed monophasic behaviour, with a short mean (sd) elimination half-life (5 [0.24] hours). After intramuscular injection its bioavailability was 100 per cent but it was absorbed slowly; its elimination half-life was satisfactorily slow (9.23 [0.74] hours). Its efficacy was evaluated in 26 crossbreed sheep with milk positive to strains of Staphylococcus aureus, coagulase-negative staphylococci and Streptococcus agalactiae, and clinical signs of disease. In 19 of them a single intramuscular dose of 6 mg/kg bodyweight resulted in a complete resolution of the clinical signs, and no microorganisms were detected in milk by the fifth day; in the other seven sheep, with more severe intramammary infections, three consecutive daily intramuscular doses of 6 mg/kg bodyweight were necessary. There were no local or systemic side effects and no relapses during 30 days after the treatments in any of the sheep.

Changing trends in mastitis

The global dairy industry, the predominant pathogens causing mastitis, our understanding of mastitis pathogens and the host response to intramammary infection are changing rapidly. This paper aims to discuss changes in each of these aspects. Globalisation, energy demands, human population growth and climate change all affect the dairy industry. In many western countries, control programs for contagious mastitis have been in place for decades, resulting in a decrease in occurrence of Streptococcus agalactiae and Staphylococcus aureus mastitis and an increase in the relative impact of Streptococcus uberis and Escherichia coli mastitis. In some countries, Klebsiella spp. or Streptococcus dysgalactiae are appearing as important causes of mastitis. Differences between countries in legislation, veterinary and laboratory services and farmers' management practices affect the distribution and impact of mastitis pathogens. For pathogens that have traditionally been categorised as contagious, strain adaptation to human and bovine hosts has been recognised. For pathogens that are often categorised as environmental, strains causing transient and chronic infections are distinguished. The genetic basis underlying host adaptation and mechanisms of infection is being unravelled. Genomic information on pathogens and their hosts and improved knowledge of the host's innate and acquired immune responses to intramammary infections provide opportunities to expand our understanding of bovine mastitis. These developments will undoubtedly contribute to novel approaches to mastitis diagnostics and control.

Identification of immunoreactive extracellular proteins of Streptococcus agalactiae in bovine mastitis

Streptococcus agalactiae is a common pathogen that causes bovine mastitis. The aims of this study were to evaluate the antibody response against S. agalactiae extracellular proteins in the whey and serum of naturally infected bovines and to identify possible immunodominant extracellular antigens. IgG1 antibodies against S. agalactiae extracellular proteins were elevated in the whey and serum of naturally infected bovines. In the whey, the levels of IgG1 specific for S. agalactiae extracellular proteins were similar in infected and noninfected milk quarters from the same cow, and the production of antibodies specific for S. agalactiae extracellular proteins was induced only by infection with this bacterium. The immunoreactivity of extracellular proteins with bovine whey was clearly different in infected versus control animals. Group B protective surface protein and 5'-nucleotidase family protein were 2 major immunoreactive proteins that were detected only in the whey of infected cows, suggesting that these proteins may be important in the pathogenesis of S. agalactiae-induced mastitis. This information could be used to diagnose S. agalactiae infection. In addition, these antigens may be useful as carrier proteins for serotype-specific polysaccharides in conjugate vaccines.

Stochastic modelling to assess economic effects of treatment of chronic subclinical mastitis caused by Streptococcus uberis

Chronic subclinical mastitis is usually not treated during the lactation. However, some veterinarians regard treatment of some types of subclinical mastitis to be effective. The goal of this research was to develop a stochastic Monte Carlo simulation model to support decisions around treatment of chronic subclinical mastitis caused by Streptococcus uberis. Factors in the model included the probability of cure after treatment, probability of the cow becoming clinically diseased, transmission of infection to other cows, and physiological effects of the infection. Using basic input parameters for Dutch circumstances, the average economic costs per cow of an untreated chronic subclinical mastitis case caused by Str. uberis in a single quarter from day of diagnosis onwards was €109. With treatment, the average costs were higher (€120). Thus, for the average cow, treatment was not efficient economically. However, the risk of high costs was much higher when cows with chronic subclinical mastitis were not treated. A sensitivity analysis showed that profitability of treatment of chronic subclinical Str. uberis mastitis depended on farm-specific factors (such as economic value of discarded milk) and cow-specific factors (such as day of diagnosis, duration of infection, amount of transmission to other cows and cure rate). Therefore, herd level protocols are not sufficient and decision support should be cow specific. Given the importance of cow-specific factors, information from the current model could be applied to automatic decision support systems.

Motivation of dairy farmers to improve mastitis management

The aims of this study were 1) to explore different motivating factors and to quantify their importance in decisions of farmers on improving mastitis management, 2) to evaluate different quality payment schemes as extra incentive mechanisms for farmers, and 3) to link the motivating factors to farmer characteristics. Data on characteristics of farmers were obtained through a traditional paper-based questionnaire (n = 100). Data on the factors motivating farmers to improve mastitis management were collected in a computer-interactive mode. Adaptive conjoint analysis was used to investigate perceptions of farmers of the importance of factors. Factors that are internal to the farm performance and the individual farmer provided more motivation than external factors implying esteem and awareness of the whole dairy sector performance. Internal nonmonetary factors relating to internal esteem and taking pleasure in healthy animals on the farm were equally motivating as monetary factors affecting farm economic performance. The identified difference in perceptions of farmers of importance of extra financial incentive based on bulk milk somatic cell count (BMSCC) depending on whether farmers think in terms of quality premium or penalty for a lower and a higher BMSCC, respectively, suggested that farmers are expected to be more motivated by a price decrease for milk with a greater BMSCC than by a price increase for milk with a lower BMSCC. In this respect, quality penalties were found to be more effective in motivating farmers than quality premiums. Two-stage cluster analysis of individual perceptions resulted in 3 distinct clusters according to motivation of farmers: premium- or penalty-oriented motivation, motivation to have an efficient (well-organized) farm that easily complies with regulatory requirements, and basic economic motivation. The obtained results highlight possible areas of improvement in incentive and educational programs aimed at improving mastitis management.

Mastite subclínica causada por Staphylococcus aureus: custo-benefício da antibioticoterapia de vacas em lactação

Avaliou-se a relação custo-benefício do tratamento da mastite subclínica bovina causada por Staphylococcus aureus. Foram selecionados 270 quartos mamários com mastite subclínica e sadios, divididos em quatro grupos de acordo com o estádio de lactação e o tratamento. O grupo 1 foi formado por animais entre 10 e 60 dias da lactação e tratados contra mastites; o grupo 2 incluiu animais entre 61 dias da lactação e dois meses antes da secagem e tratados contra mastite; o grupo 3 foi formado por animais entre 10 e 60 dias da lactação, não tratados contra mastite; e o grupo 4 foi formado por animais entre 61 dias em lactação e dois meses antes da secagem, não tratados. O tratamento foi realizado pela infusão intramamária de 150mg de gentamicina, uma vez ao dia. A reavaliação foi efetuada após 30 dias. Para os cálculos dos custos com o tratamento, foram considerados uma prevalência de S. aureus de 5% e os gastos com medicamento, descarte do leite, antibiograma e mão-de-obra. Observou-se redução de 2% e 14% das receitas nos grupos 1 e 2, respectivamente, quando comparada com as receitas obtidas antes do tratamento, demonstrando ser economicamente inviável o tratamento da mastite subclínica bovina causada por S. aureus, durante a lactação.

Economic effects of bovine mastitis and mastitis management: a review

Several studies have been published since 1990 on the economics of mastitis and mastitis management. However, hardly any of these studies has discussed the consistency of results with other studies. In the present paper, the economic factors associated with mastitis are explained, providing a framework for economic analysis. As a second step calculations of the costs of mastitis and the costs in relation to the benefits of mastitis management published since 1990 in peer-reviewed journals are extensively reviewed and analysed. The result shows a large variation in the calculated costs and benefits of mastitis and mastitis management between the different studies. Moreover, it is clear that important factors were ignored in some of the studies. The framework provided in this paper can provide a basis for analysis for future studies on the economics of mastitis and mastitis management.

Invited Review: The Role of Cow, Pathogen, and Treatment Regimen in the Therapeutic Success of Bovine Staphylococcus aureus Mastitis

Staphylococcus aureus is an important cause of udder infections in dairy herds. Both lactational and dry cow therapy are part of Staph. aureus control programs. Reported cure rates for Staph. aureus mastitis vary considerably. The probability of cure depends on cow, pathogen, and treatment factors. Cure rates decrease with increasing age of the cow, increasing somatic cell count, increasing duration of infection, increasing bacterial colony counts in milk before treatment, and increasing number of quarters infected. Staphylococcus aureus mastitis in hind quarters has a low cure rate compared with front quarters. Antimicrobial treatment of intramammary infections with penicillin-resistant Staph. aureus strains results in a lower cure rate for treatment with either beta-lactam or non-beta-lactam antibiotics. Other strain-specific factors may affect the probability of cure but routine diagnostic methods for use in bacteriology laboratories or veterinary practices are not yet available. The most important treatment factor affecting cure is treatment duration. Increased duration of treatment is associated with increased chance of cure. Economically, extended treatment is not always justified, even when indirect effects of treatment such as prevention of contagious transmission are taken into consideration. Usefulness of treatment trials could be improved by standardization of case definitions, consideration of host and strain factors, and sufficient statistical power. Treatment of young animals with penicillin-sensitive Staph. aureus infections is often justified based on bacteriological cure and economic outcome, whereas treatment of older animals, chronic infections, or penicillin-resistant isolates should be discouraged.

Effect of clinical mastitis on the lactation curve: a mixed model estimation using daily milk weights

The objective of this study was to estimate the milk production losses associated with clinical mastitis using mixed linear models and correlation structures that have not been available previously. Data used included computer-recorded daily milk yields and detailed and accurate recordings of clinical mastitis cases. Two commercial Holstein dairy farms in New York State participated in the study, one with 650 lactating cows and another that began the study with 830 lactating cows and increased to 1120 cows by the end of the study. Cows on both farms were housed in free stall barns and milked 3 times daily in milking parlors. Electrical conductivity was used as a diagnostic aid for clinical mastitis on both farms. Date of clinical onset was recorded for every episode of clinical mastitis as well as for 8 other diseases defined using standardized case definitions (dystocia, milk fever, retained placenta, metritis, ketosis, displaced abomasum, lameness, and cystic ovarian disease) during the study period of October 1, 1999 to July 31, 2001. The mixed linear model for explaining variation in the outcome variable daily milk yield relative to non-mastitic herdmates found the terms for all 9 diseases studied, including clinical mastitis, significant. The model with an autoregressive correlation structure was preferred based on -2 * log likelihood, Akaike's information criterion, and Bayesian information criterion as well as savings in degrees of freedom. Separate analyses were run for first lactation cows and for second-plus lactation cows because their lactation curves were shaped differently. Adjusting for the effects of the other 8 diseases, milk production loss from clinical mastitis during the whole lactation was estimated as approximately 598 kg for second-plus lactation cows. However, cows that contracted mastitis had a daily production advantage of 2.6 kg over their herdmates until they contracted the disease. When compared with this potentially higher milk production, the total loss from clinical mastitis was estimated as 1181 kg.

Pharmaco-epidemiology and -economics should be developed more extensively in veterinary medicine

Pharmaco-epidemiology, which has emerged within the last 20 years as a new discipline in human medicine, deals with the quantities of drugs consumed and their effects on populations in terms of epidemiological concepts and tools. To a lesser extent, it is also practised in veterinary medicine. The applications presented in this review are illustrative of pharmaco-epidemiological and -economical concepts. Assessment of drug consumption, the study of adverse drug effects, and the economic implications of drug use are the three main fields considered. Developments can be expected in veterinary medicine within the next few years relative to novel areas of interest such as antimicrobial resistance and new therapeutic class uses. These applications will require methodological progress and the elimination of current gaps. Pharmaco-epidemiological methods need to be developed, which implies close co-operation between statisticians, pharmacologists, veterinary practitioners and epidemiologists. A greater use of the term 'pharmaco-epidemiology' as a keyword in literature would facilitate recognition of this domain which associates closely epidemiology and pharmacology.

A PCR-based method for the detection of Streptococcus agalactiae in milk

Bovine mastitis caused by Streptococcus agalactiae is mainly subclinical and therefore can be diagnosed only in the laboratory. We developed a polymerase chain reaction (PCR)-based method for specific and sensitive detection of S. agalactiae in raw milk. The specificity of the PCR reaction is based on unique S. agalactiae DNA sequences within the 16S subunit of the rRNA genes. Two pairs of sequences were used as positive controls; general streptococci primers, which anneal to conserved areas within the 16S rRNA subunit gene, and primers, which anneal to sequences within bovine mitochondrial DNA. The method of detection includes selective enrichment of S. agalactiae in the milk sample, followed by DNA extraction using a rapid and simple procedure developed for this purpose, and specific PCR reaction with appropriate controls. The method enables the detection of one bacterium in 1 ml of raw milk. The method developed can be easily incorporated as part of routine screening of bulk milk collection tanks for early detection of infected cows in a herd.

Bovine mastitis and intramammary drug delivery: review and perspectives

Intramammary infections (IMIs) represent a major feature in bovine pathology. The treatment of IMIs concern antimicrobial substances. Therapeutic strategies involve administration of immediate release formulations during lactation with or without long-acting formulations during the dry period. Current treatments are not very successful and cure rates are poor, especially towards Staphylococcus aureus which is responsible for chronic infections and huge economic losses. New strategies have recently been investigated. These include particular immunomodulators like lysostaphin or cytokines, and novel formulations (e.g. liposomes, microparticles or nanoparticles) that allow uptake of the active component by phagocytes and thus prolong an enhanced antibacterial activity.

Disease management research using event graphs

Event Graphs, conditional representations of stochastic relationships between discrete events, simulate disease dynamics. In this paper, we demonstrate how Event Graphs, at an appropriate abstraction level, also extend and organize scientific knowledge about diseases. They can identify promising treatment strategies and directions for further research and provide enough detail for testing combinations of new medicines and interventions. Event Graphs can be enriched to incorporate and validate data and test new theories to reflect an expanding dynamic scientific knowledge base and establish performance criteria for the economic viability of new treatments. To illustrate, an Event Graph is developed for mastitis, a costly dairy cattle disease, for which extensive scientific literature exists. With only a modest amount of imagination, the methodology presented here can be seen to apply modeling to any disease, human, plant, or animal. The Event Graph simulation presented here is currently being used in research and in a new veterinary epidemiology course.

Simulated effects on dairy cattle health of extending the voluntary waiting period with recombinant bovine somatotropin

We simulated the effect of extending the voluntary wait period by 100 days on disorder-frequency measures that were based on cow-years (from lactations completed during the 4-year simulation horizon), metric tons of milk yield, and lactational incidence risks. A dynamic stochastic discrete-event simulation model that focuses on clinical and subclinical intramammary infections (IMI), plus clinical metabolic (left-displaced abomasum, ketosis, milk fever) and reproductive (cystic ovarian disease, dystocia, retained placenta, twinning, uterine infection) disorders in dairy herds was used. Although the voluntary wait period was increased by 100 days (50 vs. 150), the predicted difference in simulated days to conception was only 89 days for the extended voluntary wait-period group (which we attributed to higher fertility later in lactation). Herds that had a voluntary wait period of 150 days (compared to the control herds' voluntary wait period of 50 days) were predicted to have significantly lower rates of metabolic and reproductive disorders and clinical mastitis on both cow-year and milk-yield bases. Simulated control herds, on average, produced 8539 kg of milk in an average lactation of 325 days and simulated herds with a 150-day voluntary wait period 10893 kg of milk in an average lactation of 409 days. There was a significantly lower predicted rate and risk of culling for reproductive failure in the extended voluntary wait period group. The predicted lactational incidence risks for subclinical IMI were 18% higher for the extended voluntary wait period group - but extending the voluntary wait period by 100 days was predicted not to increase the risk of any of the other 10 disorders.